Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus docetaxel in recurrent/metastatic squamous cell carcinoma of the head and neck after platinum failure
2015-002325-18Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Medical University of Vienna. Primary endpoints: Safety, Overall response rate and 1 more. Started Dec 2015; status: completed.
02
Drugs
pembrolizumabdocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2015-002325-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002325-18.